V
Viridian Therapeutics D
D
VRDN
20.820
USD
0.62
(3.07%)
Market Open
Volume
13,164
EPS
-4
Div Yield
-
P/E
-5
Market Cap
1,656,338,540
Novo Nordisk Surges in Profit and Sales
6 months ago
Stocks news More
Title: Viridian Therapeutics
Sector: Healthcare
Industry: Biotechnology
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.